Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution

被引:2
|
作者
Armas, Sebastian [1 ]
Huertas-Ayala, Carolina [2 ]
Chan, Randall Y. [3 ,4 ]
Chi, Yueh-Yun [3 ]
Huh, Winston W. [3 ,5 ]
Termuhlen, Amanda [6 ]
Gaynon, Paul S. [3 ,5 ]
Kovach, Alexandra E. [7 ,8 ]
Doan, Andrew [3 ,5 ]
机构
[1] Loma Linda Univ, Sch Med, Loma Linda, CA USA
[2] San Juan Bautista Sch Med, Caguas, PR USA
[3] Univ Southern Calif, Dept Pediat, Keck Sch Med, Los Angeles, CA USA
[4] Los Angeles Cty Univ, Southern Calif Med Ctr, Dept Pediat, Los Angeles, CA USA
[5] Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA
[6] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA
[7] Univ Southern Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA USA
[8] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90027 USA
关键词
ABVD; ABVE-PC; Hodgkin lymphoma; pediatric; CHILDREN; CHEMOTHERAPY; THERAPY; ADOLESCENTS; TERM; MANAGEMENT;
D O I
10.1002/pbc.29601
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to describe the single-institution experience of using both regimens in patients with pediatric HL. Methods This retrospective cohort study evaluated a total of 224 patients diagnosed with HL between 1999 and 2018 at Children's Hospital Los Angeles (CHLA), of which 93 patients were eligible having received ABVD (n = 46) or ABVE-PC (n = 47) chemotherapy as their initial treatment. Descriptive analyses were performed using the Student's t-test or Fisher's exact test. Survival analysis used the Kaplan-Meier method. Events included death, relapse, and secondary malignancy. We also describe the use of radiation therapy, pulmonary toxicity, and cardiomyopathy determined by shortening fraction There was no difference in baseline characteristics between the patients receiving ABVE-PC or ABVD in regard for stage, risk group, or prognostic variables, such as the presence or absence of "B" symptoms, bulky disease, and extra-nodal involvement. A greater proportion of patients treated with ABVE-PC received consolidating external beam radiation treatment (XRT) either by randomization or by response compared to ABVD (59.6% vs. 32.6%, respectively, p = .01). While not statistically significant, response to therapy, assessed by positron emission tomography/computerized tomography (PET/CT) where available, mirrored the use for radiation (rapid response 58.3% vs. 90.0%, n = 34, p = .11). The median dose of anthracycline (doxorubicin) was the same in patients receiving ABVE-PC versus ABVD (200 vs. 200 mg/m(2), interquartile range 200-250 vs. 200-300 mg/m(2), p = .002). There was no difference in event-free survival (p = .63) or overall survival (p = .37) with a median follow-up length of 3.9 years. Conclusions ABVD and ABVE-PC achieved similar survival outcomes in our single-institution cohort.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor
    Gastaldi, R
    Martino, P
    Gentile, G
    Picardi, V
    De Propris, MS
    Pirillo, MF
    De Vellis, A
    Mandelli, F
    ANNALS OF ONCOLOGY, 2002, 13 (07) : 1158 - 1160
  • [22] Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    Straus, DJ
    Portlock, CS
    Qin, J
    Myers, J
    Zelenetz, AD
    Moskowitz, C
    Noy, A
    Goy, A
    Yahalom, J
    BLOOD, 2004, 104 (12) : 3483 - 3489
  • [23] ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as front-line therapy for Hodgkins lymphoma in Hispanic patients: A single center experience from Texas-Mexico Border.
    Gaur, Sumit
    Philipovskiy, Alexander
    Dwivedi, Alok Kumar
    Eiring, Ana
    Onyedika, Umeanaeto
    Orazi, Attilio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy
    Gandikota, Neetha
    Hartridge-Lambert, Sidonie
    Migliacci, Jocelyn C.
    Yahalom, Joachim
    Portlock, Carol S.
    Schoeder, Heiko
    CANCER, 2015, 121 (12) : 1985 - 1992
  • [27] 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma:: Results of a pilot study of the German Hodgkin's Lymphoma Study Group
    Sieber, M
    Bredenfeld, H
    Josting, A
    Reineke, T
    Rueffer, U
    Koch, T
    Naumann, R
    Boissevain, F
    Koch, P
    Worst, P
    Soekler, M
    Eich, H
    Müller-Hermelink, HK
    Franklin, J
    Paulus, U
    Wolf, J
    Engert, A
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1734 - 1739
  • [28] Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
    Durmo, Rexhep
    Donati, Benedetta
    Rebaud, Louis
    Cottereau, Anne Segolene
    Ruffini, Alessia
    Nizzoli, Maria Elena
    Ciavarella, Sabino
    Vegliante, Maria Carmela
    Nioche, Christophe
    Meignan, Michel
    Merli, Francesco
    Versari, Annibale
    Ciarrocchi, Alessia
    Buvat, Irene
    Luminari, Stefano
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 645 - 657
  • [29] HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
    Montoto, Silvia
    Shaw, Kate
    Okosun, Jessica
    Gandhi, Shreyans
    Fields, Paul
    Wilson, Andrew
    Shanyinde, Milensu
    Cwynarski, Kate
    Marcus, Robert
    de Vos, Johannes
    Young, Anna Marie
    Tenant-Flowers, Melinda
    Orkin, Chloe
    Johnson, Margaret
    Chilton, Daniella
    Gribben, John G.
    Bower, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4111 - 4116
  • [30] PHASE-III TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) VERSUS CISPLATIN, ETOPOSIDE, BLEOMYCIN AND PREDNISONE (CISEBP) FOR THE TREATMENT OF ADVANCED NON-HODGKINS-LYMPHOMA OF HIGH-GRADE MALIGNANCY
    ANDERSEN, J
    THORLING, K
    BENTZEN, SM
    BRINCKER, H
    CHRISTENSEN, BE
    PEDERSEN, M
    ACTA ONCOLOGICA, 1990, 29 (08) : 995 - 999